No Molecule Left Behind: Inside the Companies Rescuing Abandoned Rare Disease…
More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000…
Joseph leads PharmaBoardroom's coverage of the North American and Northern European regions. He holds a BSc in International Marketing from Rowan University and a MSc in Healthcare Innovation from Copenhagen Business School. Joseph is particularly interested in healthcare policy, rare disease and CGT advocacy, public-private partnership, and the cross-functional engagement of healthcare stakeholde more...
More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000…
Boston and the Bay Area are globally renowned life science hubs, but beyond these more well-known centers of excellence lies a dense network of states and cities with enticing and…
Just over one year into the second Trump administration, the US healthcare and life science market is navigating a steady stream of series of unprecedented policy shifts. Long defined by…
When Nasha Fitter’s daughter, Amara, was diagnosed with the ultra-rare FOXG1 syndrome at just seven months old, the prognosis was stark: no speech, no independent movement, severe intellectual disability, and…
The latest updates from the US healthcare and life sciences scene. Eli Lilly partners with Nvidia to build a supercomputer for faster drug discovery; Trump secures “most-favored-nation” pricing deals with…
In 2025, just 318 US biotech deals closed in Q2 – the lowest in a decade – even as mega-rounds propped up total investment volumes. For a sector that was…
The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial…
The latest stories from healthcare and the life sciences in the US. Vinay Prasad is reinstated as head of the FDA’s CBER following a brief resignation; HHS fires Gray Delany…
The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to…
As clinical trials increasingly drift toward Asia and the US, can Denmark offer a blueprint for revitalising Europe’s competitive edge? As Europe’s leader in clinical trials per capita, Denmark…
As Denmark prepares to assume the rotating presidency of the Council of the European Union on July 1st of 2025, attention is turning to what this small yet strategically positioned…
Already one of Europe’s top countries for clinical trials per capita, Denmark has further strengthened its position in recent years. The number of active trials in the country rose from…
See our Cookie Privacy Policy Here
